HOME >> MEDICINE >> NEWS
Combined contrast enhanced MRI shows promise

Combined contrast enhanced (CCE) MRI, in which two contrast agents are used together, permits accurate non-invasive staging of liver fibrosis in non-alcoholic fatty liver disease (NAFLD), according to a new study by researchers from the University of California, San Diego.

For the study, the researchers reviewed 26 patients with NAFLD who underwent CCE MRI. Using a five-point scale, the researchers found that the staging of the NAFLD on CCE MRI closely matched the staging of NAFLD using conventional pathology.

According to the researchers, the prevalence of NAFLD is increasing in western nations and is a major health problem affecting both children and adults. It is a common cause of cirrhosis in American adults and the most common cause in children.

The definitive method of diagnosis and staging is liver biopsy, but it has several limitations, say the researchers. It is invasive, costly, has risks and only samples about 1/50,000th of the liver. "This sampling issue is important because the pathological processes that affect the NAFLD liver are not evenly distributed throughout, so that tiny changes in needle placement will result in potentially large changes in biopsy interpretation. Because of these limitations, alternative methods such as CCE MR need to be developed," said Claude Sirlin, MD, lead author of the study.

"Except for CCE MR, all other experimental techniques rely on surrogate or indirect markers of fibrosis. CCE MR attempts to directly visualize fibrosis by using two contrast agents with complementary mechanisms, iron particles to darken the background liver and gadolinium to brighten the fibrosis," said Dr. Sirlin, "Gadolinium alone and iron particles alone are not adequate for visualization of fibrosis, unless the fibrosis is extremely advanced. However, when given together, the agents show fibrosis with high clarity," he added.

The combined use of two or more complementary contrast agents is uncommon in r
'"/>

Contact: Necoya Lightsey
necoya@arrs.org
604-647-7413
American Roentgen Ray Society
1-May-2006


Page: 1 2

Related medicine news :

1. Combined molecular-targeted and hormonal therapies offer promise in treating ovarian cancer
2. Combined imaging approach may provide better identification of difficult-to-diagnose brain clots
3. Combined therapies may boost immune response and long-term protection against brain tumors
4. Combined liver-kidney transplant beneficial for patients with dual organ disease
5. Combined treatment cuts inflammatory cells in chronic obstructive pulmonary disease
6. Combined MRI and mammography more effective at detecting breast cancer in high-risk women
7. Fluorescence diffuse optical tomography provides high contrast, 3-D look at breast cancer
8. MRI contrast agent can detect heart attack in the making
9. High-resolution imaging with contrast agent shows promise in osteoarthritis research
10. Using contrast enhanced sonography improves diagnosis of liver and spleen injuries
11. Reducing contrast material injection in elderly patients can lower cost of exam and risks

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... DUBLIN , June 27, 2016 Jazz ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... proposed acquisition of Celator Pharmaceuticals, Inc. ("Celator"; Nasdaq: ... 11:59 p.m. (Eastern Daylight Time). As previously ... entered into a definitive merger agreement under which Jazz ...
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... Dehaier Medical Systems Ltd. (NASDAQ: DHRM ) ... medical devices and wearable sleep respiratory products in ... with Hongyuan Supply Chain Management Co., Ltd. (hereinafter referred ... to develop Dehaier,s new Internet medical technology business. ... Hongyuan Supply Chain,s sales platform to reach Dehaier,s dealers ...
Breaking Medicine Technology:
Cached News: